COVID-19 acute respiratory distress syndrome : A simulation study of the effects of combination therapy with tocilizumab and siltuximab
© 2021 British Pharmacological Society..
AIMS: To assess the potential of interleukin-6 (IL-6) signalling blockade in the lung to treat SARS-CoV-2 infection via model-based simulation by exploring soluble IL-6 receptor (sIL-6R) sequestration by tocilizumab (TCZ) and IL-6 sequestration by siltuximab (SIL).
METHODS: Literature values of IL-6, IL-6 antagonist SIL, sIL-6R, IL-6R antagonist TCZ and their respective binding constants were used to develop a model to predict the impact of treatment on IL-6 signalling. Models were used to generate simulated bronchoalveolar lavage fluid concentrations for normal subjects, subjects at risk of developing acute respiratory distress syndrome (ARDS), and subjects with ARDS under 4 conditions: without treatment; treatment with TCZ; treatment with SIL; and treatment with TCZ + SIL.
RESULTS: With TCZ intervention, IL-6 levels are unaffected and sIL-6R is reduced somewhat below the Normal case. IL-6:sIL-6R complex only slightly decreased relative to the no-intervention case. With SIL intervention, sIL-6R levels are unaffected and IL-6 is greatly reduced below the Normal case. IL-6:sIL-6R complex is greatly decreased relative to the no-intervention case. With TCZ + SIL intervention, IL-6 and sIL-6R levels are reduced below the Normal case and achieve suppression equivalent to monotherapy results for their respective targets. IL-6:sIL-6R complex reduction is predicted to be greater than that achieved with monotherapy. This reflects sequestration of both components of the complex and the nonlinear binding equilibrium.
CONCLUSION: Coadministration of both IL-6 and IL-6R sequestering products such as SIL and TCZ may be necessary to effectively treat COVID-19 patients who have or are at risk of developing ARDS.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
---|---|
Enthalten in: |
British journal of clinical pharmacology - 88(2022), 3 vom: 27. März, Seite 1043-1053 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Doyle, Eileen B [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute respiratory distress syndrome |
---|
Anmerkungen: |
Date Completed 24.02.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/bcp.15009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM328632163 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM328632163 | ||
003 | DE-627 | ||
005 | 20231225203339.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bcp.15009 |2 doi | |
028 | 5 | 2 | |a pubmed24n1095.xml |
035 | |a (DE-627)NLM328632163 | ||
035 | |a (NLM)34318516 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Doyle, Eileen B |e verfasserin |4 aut | |
245 | 1 | 0 | |a COVID-19 acute respiratory distress syndrome |b A simulation study of the effects of combination therapy with tocilizumab and siltuximab |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.02.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 British Pharmacological Society. | ||
520 | |a AIMS: To assess the potential of interleukin-6 (IL-6) signalling blockade in the lung to treat SARS-CoV-2 infection via model-based simulation by exploring soluble IL-6 receptor (sIL-6R) sequestration by tocilizumab (TCZ) and IL-6 sequestration by siltuximab (SIL) | ||
520 | |a METHODS: Literature values of IL-6, IL-6 antagonist SIL, sIL-6R, IL-6R antagonist TCZ and their respective binding constants were used to develop a model to predict the impact of treatment on IL-6 signalling. Models were used to generate simulated bronchoalveolar lavage fluid concentrations for normal subjects, subjects at risk of developing acute respiratory distress syndrome (ARDS), and subjects with ARDS under 4 conditions: without treatment; treatment with TCZ; treatment with SIL; and treatment with TCZ + SIL | ||
520 | |a RESULTS: With TCZ intervention, IL-6 levels are unaffected and sIL-6R is reduced somewhat below the Normal case. IL-6:sIL-6R complex only slightly decreased relative to the no-intervention case. With SIL intervention, sIL-6R levels are unaffected and IL-6 is greatly reduced below the Normal case. IL-6:sIL-6R complex is greatly decreased relative to the no-intervention case. With TCZ + SIL intervention, IL-6 and sIL-6R levels are reduced below the Normal case and achieve suppression equivalent to monotherapy results for their respective targets. IL-6:sIL-6R complex reduction is predicted to be greater than that achieved with monotherapy. This reflects sequestration of both components of the complex and the nonlinear binding equilibrium | ||
520 | |a CONCLUSION: Coadministration of both IL-6 and IL-6R sequestering products such as SIL and TCZ may be necessary to effectively treat COVID-19 patients who have or are at risk of developing ARDS | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a IL-6 | |
650 | 4 | |a acute respiratory distress syndrome | |
650 | 4 | |a modelling | |
650 | 4 | |a siltuximab | |
650 | 4 | |a simulation | |
650 | 4 | |a tocilizumab | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
650 | 7 | |a siltuximab |2 NLM | |
650 | 7 | |a T4H8FMA7IM |2 NLM | |
700 | 1 | |a Bentley, Darren |e verfasserin |4 aut | |
700 | 1 | |a Dodds, Michael G |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 88(2022), 3 vom: 27. März, Seite 1043-1053 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
773 | 1 | 8 | |g volume:88 |g year:2022 |g number:3 |g day:27 |g month:03 |g pages:1043-1053 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15009 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 88 |j 2022 |e 3 |b 27 |c 03 |h 1043-1053 |